|
Miltenyi Biotec
inf γ ![]() Inf γ, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/IFN-%CE%B3+Antibody%2C+anti-human/pmc08944951-1-0-6 Average 94 stars, based on 1 article reviews
inf γ - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Boster Bio
m00398 ![]() M00398, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/Anti-Cytokeratin+5+Antibody+Picoband/pm41707646-436-44-42 Average 94 stars, based on 1 article reviews
m00398 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
anti ifn γ apc ![]() Anti Ifn γ Apc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/APC+Anti-Mouse+IFN-%CE%B3+Antibody/pmc12126593-245-30-64 Average 94 stars, based on 1 article reviews
anti ifn γ apc - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
antibodies against human ifn γ ![]() Antibodies Against Human Ifn γ, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/FITC+Anti-Human+IFN-%CE%B3+Antibody/pm40520230-78-17-22 Average 93 stars, based on 1 article reviews
antibodies against human ifn γ - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
pe anti human interferon gamma ifn γ antibody ![]() Pe Anti Human Interferon Gamma Ifn γ Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/APC+Anti-Human+IFN-%CE%B3+Antibody/pmc12718725-65-2-8 Average 93 stars, based on 1 article reviews
pe anti human interferon gamma ifn γ antibody - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Elabscience Biotechnology
ifnγ ![]() Ifnγ, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/FITC+Anti-Mouse+IFN-%CE%B3+Antibody/pm39278093-100-59-65 Average 94 stars, based on 1 article reviews
ifnγ - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Bio X Cell
ifn γ ![]() Ifn γ, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/InVivoMAb+anti-mouse+IFN%CE%B3/pm34362900-278-3-14 Average 93 stars, based on 1 article reviews
ifn γ - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Bio X Cell
ifn ![]() Ifn, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/InVivoMAb+anti-mouse+IFN%CE%B3/pmc06975265-487-49-53 Average 95 stars, based on 1 article reviews
ifn - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
Bio X Cell
anti ifn γ ![]() Anti Ifn γ, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/InVivoPlus+anti-mouse+IFN%CE%B3/pmc06458273-148-1-13 Average 96 stars, based on 1 article reviews
anti ifn γ - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
Bio X Cell
invivomab anti human ifnγ ![]() Invivomab Anti Human Ifnγ, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/InVivoMAb+anti-human+IFN%CE%B3/pmc12647259-339-9-13 Average 94 stars, based on 1 article reviews
invivomab anti human ifnγ - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
αifnγ ![]() αifnγ, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/anti+ifn%CE%B3+antibody/IFN-%CE%B3+Antibody%2C+anti-mouse/pmc12223510-360-7-8 Average 93 stars, based on 1 article reviews
αifnγ - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Biomedicines
Article Title: Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19
doi: 10.3390/biomedicines10030630
Figure Lengend Snippet: List of fluorochrome-labeled antibodies used in flow cytometry studies. FITC, fluorescein isothiocyanate; PE, phycoerythrin; PE/Cy7, tandem comprising phycoerythrin and cyanine 7; APC, allophycocyanin; APC/Cy7, tandem comprising allophycocyanin and cyanine 7.
Article Snippet:
Techniques: Flow Cytometry
Journal: Journal of the Chinese Medical Association : JCMA
Article Title: Phenylalanyl-tRNA synthetase subunit beta downregulation by spi1 proto-oncogene modulates lung adenocarcinoma progression and immune microenvironment via mammalian target of rapamycin pathway
doi: 10.1097/JCMA.0000000000001286
Figure Lengend Snippet: FARSB promotes tumorigenesis and anti-tumor immunity in LUAD. A, qRT-PCR analysis of FARSB mRNA levels in different cell groups (si-NC, control group; si-FARSB, FARSB knockdown group). B, WB analysis of FARSB protein expression in various cell groups. C, CCK-8 assay evaluating the effect of FARSB knockdown on cell viability. D, EdU assay assessing the impact of FARSB knockdown on cell proliferation. E and F, Flow cytometry analysis of the effect of FARSB knockdown on cell apoptosis. G, WB analysis of PD-L1 (an immune checkpoint protein) expression levels. H, CFSE fluorescence staining assessing CD8 + T cell proliferation (CFSE dye dilution measures CD8 + T cell division). I-K, Flow cytometry analysis of IFN-γ (I), GZMB (J), and TNF-α (K) expressions in tumor-infiltrating CD8 + T cells; these cytokines reflect CD8 + T cell cytotoxic function. N = 3, *** p < 0.001 and **** p < 0.0001 denote statistical significance. CFSE = carboxyfluorescein succinimidyl ester; FARSB = phenylalanyl-tRNA synthetase subunit beta; GZMB = Granzyme B; IFN-γ = interferon-gamma; LUAD = lung adenocarcinoma; PD-L1 = programmed death-ligand 1; TNF-α = tumor necrosis factor-alpha; WB = western blot.
Article Snippet: Antibodies included:
Techniques: Quantitative RT-PCR, Control, Knockdown, Expressing, CCK-8 Assay, EdU Assay, Flow Cytometry, Fluorescence, Staining, Western Blot
Journal: Journal of the Chinese Medical Association : JCMA
Article Title: Phenylalanyl-tRNA synthetase subunit beta downregulation by spi1 proto-oncogene modulates lung adenocarcinoma progression and immune microenvironment via mammalian target of rapamycin pathway
doi: 10.1097/JCMA.0000000000001286
Figure Lengend Snippet: FARSB Activates the mTOR signaling pathway, promoting LUAD tumorigenesis and anti-tumor immunity. A, GSEA analysis of enriched pathways associated with differential FARSB expression in LUAD. B, WB analysis of the expression of the pathway-related proteins p-mTOR, mTOR, p-p70S6K, p70S6K, p-4EBP1, and 4EBP1. C, CCK-8 assays evaluating cell viability. D, EdU assays assessing cell proliferation. E, Flow cytometry analysis of cell apoptosis. F, WB analysis of PD-L1 expression levels. G, CFSE fluorescence staining assessing CD8 + T cell proliferation. H-J, Flow cytometry analysis of IFN-γ (H), GZMB (I), and TNF-α (J) expressions in tumor-infiltrating CD8 + T cells; these cytokines reflect CD8 + T cell cytotoxic function. n = 3, ** p < 0.01, *** p < 0.001, **** p < 0.0001 denote statistical significance. CFSE = carboxyfluorescein succinimidyl ester; FARSB = phenylalanyl-tRNA synthetase subunit beta; GZMB = Granzyme B; IFN-γ = interferon-gamma; LUAD = lung adenocarcinoma; mTOR = mammalian target of rapamycin; ns = no significant differences; PD-L1 = programmed death-ligand 1; TNF-α = tumor necrosis factor alpha; WB = western blot.
Article Snippet: Antibodies included:
Techniques: Expressing, CCK-8 Assay, Flow Cytometry, Fluorescence, Staining, Western Blot
Journal: Journal of the Chinese Medical Association : JCMA
Article Title: Phenylalanyl-tRNA synthetase subunit beta downregulation by spi1 proto-oncogene modulates lung adenocarcinoma progression and immune microenvironment via mammalian target of rapamycin pathway
doi: 10.1097/JCMA.0000000000001286
Figure Lengend Snippet: SPI1 Downregulates FARSB to modulate the mTOR signaling pathway, thus influencing LUAD progression and anti-tumor immunity. A, qRT-PCR analysis of FARSB and SPI1 mRNA levels in different cell groups. B, WB analysis of FARSB and SPI1 protein expression. C and D, WB analysis of mTOR signaling pathway-related proteins. E, CCK-8 assays evaluating cell viability. F, EdU assays assessing cell proliferation. G, Flow cytometry analysis of cell apoptosis. H, WB analysis of PD-L1 expression levels. I: CFSE fluorescence staining assessing CD8 + T cell proliferation. J-L: Flow cytometry analysis of IFN-γ (J), GZMB (K), and TNF-α (L) expressions in tumor-infiltrating CD8 + T cells; these cytokines reflect CD8+ T cell cytotoxic function. n = 3, *** p < 0.001, **** p < 0.0001 denote statistical significance. FARSB = phenylalanyl-tRNA synthetase subunit beta; GZMB = Granzyme B; IFN-γ = interferon-gamma; LUAD = lung adenocarcinoma; mTOR = Mammalian target of rapamycin; ns = no significant differences or significant correlation.; PD-L1 = programmed death-ligand 1; qRT-PCR = quantitative reverse transcription-polymerase chain reaction; TNF-α = tumor necrosis factor alpha; WB = western blot.
Article Snippet: Antibodies included:
Techniques: Quantitative RT-PCR, Expressing, CCK-8 Assay, Flow Cytometry, Fluorescence, Staining, Reverse Transcription, Polymerase Chain Reaction, Western Blot
Journal: Biochemical and biophysical research communications
Article Title: Immune escape between endoplasmic reticulum stress-related cancer cells and exhausted CD8+T cells leads to neoadjuvant chemotherapy resistance in ovarian cancer.
doi: 10.1016/j.bbrc.2024.150686
Figure Lengend Snippet: Fig. 8. Inhibition of NECTIN2 expression in ID8 cells can promote the cytotoxic function of co-cultured CTLs. a The expressions of PD1, PRF1 and IFNγ in CTLs cocultured with ID8 cells were detected by flow cytometry, n = 3. b-d Histogram plots show the proportion of PD1+ CTLs (b), PRF1+ CTLs (c) and IFNγ+ CTLs (d) in all CTLs co-cultured with ID8 cells in each group, n = 3.
Article Snippet: The transfected ID8 cells were co-cultured with the CTLs following stimulation by 8.5 μM cisplatin or the same volume of PBS (control group) for 24 h. CTLs in the supernatant were collected and the expression of depletion marker PD1(PE/DazzleTM 594 anti-mouse CD279 (PD1) Antibody, 109116, Biolegend, USA) and cytotoxic marker PRF1 (APC anti-mouse Perforin Antibody, 154304, Biolegend, USA) and
Techniques: Inhibition, Expressing, Cell Culture, Flow Cytometry
Journal: Signal Transduction and Targeted Therapy
Article Title: Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
doi: 10.1038/s41392-025-02476-5
Figure Lengend Snippet: Excessive intestinal tissue injury and regeneration are linked by IFNγ and T reg cells. a BALB/c mice received 9 Gy TBI followed by allo-BMT (C57BL/6 J donors) of BM ± allogeneic T cells (low dose: 0.1 × 10 6 T cells; medium dose: 0.5 × 10 6 T cells; high dose: 2.5 × 10 6 T cells). Correlation between maximum weight loss (day 7) and peak weight recovery 2 weeks after allo-BMT. The data were pooled from 3 independent experiments. b Ex vivo small intestine (SI) organoid regeneration rate ( = number of established organoids on day 4 after starting ex vivo organoid culture divided by the number of cultured crypts, see Fig. for details) on day 7 after allo-BMT in mice co-transplanted with increasing numbers (low, medium, high) of allogeneic T cells or ( c ) increasing doses of TBI conditioning prior to allo-BMT with a medium dose of T cells. The data were pooled from 3 independent experiments. d Survival and e weight loss of individual mice after they received TBI (9 Gy) followed by allo-BMT (C57BL/6 J donors) with Ifng +/+ BM and Ifng +/+ or Ifng −/− T conv cells (C57BL/6 J donors). Pooled data from 2 independent experiments. f Intestinal FITC-dextran permeability assay two weeks (d16) after allo-BMT. Pooled data from 3 experiments. g Allo-BMT with WT BM and a low or high dose of Ifng +/+ or Ifng −/− T cells. Ex vivo SI organoid regeneration rate. Pooled data from 4 experiments. h SI intraepithelial leukocytes were isolated one week after allo-BMT and analyzed via flow cytometry after 4 h of restimulation in vitro. Frequency of FoxP3 + CD4 + donor (H-2K b+ ) T reg cells among all live CD45 + immune cells. i Allo-BMT with BM and 1 × 10 6 T cells ± ruxolitinib treatment (30 mg/kg body weight, administered orally twice daily from day –1 prior to allo-BMT until the day before analysis). The intraepithelial donor T reg cells are depicted on day 7 after allo-BMT. j Allo-BMT with BM and a low or high dose of T cells ± ruxolitinib treatment from d-1 onward (30 mg/kg body weight, administered orally twice daily). Ex vivo SI organoid regeneration rate on day 7 after allo-BMT. Pooled data from 4 independent experiments. The data of the control group, which included a low dose of T cells and a high dose of T cells, are also shown in Fig. 1g. The data in Fig. 1b, c, f–j are presented as the means ± S.E.M.s and were analyzed via unpaired two-tailed t tests or Kruskal‒Wallis tests (Fig. 1b, c, g, j) with Dunn’s multiple comparisons test for multiple comparisons. The number of biological replicates ( n ), indicating the number of mice analyzed, is shown in the figure for all individual experiments
Article Snippet: Blocking antibodies (InVivoMAb anti-mouse IL-10R (CD210), InVivoMAb anti-mouse IFNγ,
Techniques: Ex Vivo, Cell Culture, FITC-Dextran Permeability Assay, Isolation, Flow Cytometry, In Vitro, Control, Two Tailed Test
Journal: Signal Transduction and Targeted Therapy
Article Title: Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
doi: 10.1038/s41392-025-02476-5
Figure Lengend Snippet: T reg cells adapt to intestinal epithelial tissue injury via IFNγ expression. a A published scRNA-seq dataset (GEO accession number: GSE223798 ) was used. Briefly, donor T reg cells were expanded in vitro, analyzed (input T reg cells) or supplied to recipient mice and then extracted from the respective tissues. Plots of single cells in UMAP space for all experimental conditions, colored by their origin or b colored by their IFNγ expression (library size normalized and log-transformed UMI counts). c IFNγ expression (library-size normalized and log-transformed UMI counts) in tissue and input T reg cells (Input n = 3068, Colon n = 14,862, Liver n = 10,153, Spleen n = 8606, 3 mice). Differential expression testing was performed with the Wilcoxon test, and the resulting p -values were corrected for multiple testing with the Bonferroni method. d Exemplary image of chip cytometry of intestinal biopsies of human allo-HSCT recipients. Upper image: overlay of all indicated markers in a larger area (scale bar = 50 µm). Lower images: high-resolution images of single markers and their overlay for three representative single cells (scale bar = 10 µm). e IFNγ expression (library-size normalized UMI counts) of T reg cells was analyzed via scRNA-seq of cells isolated from large intestinal biopsies of allo-HCST recipients ( n = 22 patients, with n = 208 identified T reg cells) or control patients who did not undergo allo-HSCT ( n = 5 patients with n = 34 identified T reg cells). f C57BL/6 J Ifng +/+ or Ifng −/− mice received abdominal irradiation (ABI, 5 × 4.5 Gy/day from day 0 until day 4), and body weight was monitored. Pooled data from 2 experiments. Statistical comparisons are shown for the day of weight nadir (day 6) and for days 9, 11, and 13 of the recovery phase. g Intestinal FITC-dextran permeability assay on day 7 following ABI (5 × 4.5 Gy/day). Pooled data from 2 independent experiments. h Ex vivo SI organoid regeneration rate on day 7 following ABI in Ifng +/+ or Ifng −/− mice. Pooled data from 2 experiments. i SI and large intestine (LI) intraepithelial leukocytes were analyzed by flow cytometry. The cells were isolated at different time points (7, 15, and 30 days) following ABI of the C57BL/6 J WT mice. Control mice without an ABI were pooled and are shown as day 0 after ABI. The graphs show the percentages of T reg cells among all live CD45 + immune cells. Pooled data from 7 experiments. j Graph showing the percentage of IFNγ + T reg cells among all live CD45 + intraepithelial leukocytes in C57BL/6 J WT mice on day 15 after the start of ABI, as analyzed by flow cytometry after in vitro restimulation. The data were pooled from 3 independent experiments. The data are presented as the means ± S.E.M.s and were analyzed via unpaired two-tailed t tests, Mann‒Whitney tests ( e , h ), or ordinary one-way ANOVA (with Dunn’s multiple comparisons test) for multiple comparisons. The data presented in ( g ) were analyzed via an unpaired one-tailed t test on the basis of the hypothesis of increased injury in Ifng −/− mice, as suggested by the results shown in ( f ). The number of biological replicates ( n ), indicating the number of mice analyzed, is shown in the figure for all individual experiments
Article Snippet: Blocking antibodies (InVivoMAb anti-mouse IL-10R (CD210), InVivoMAb anti-mouse IFNγ,
Techniques: Expressing, In Vitro, Transformation Assay, Quantitative Proteomics, Chip Cytometry, Isolation, Control, Irradiation, FITC-Dextran Permeability Assay, Ex Vivo, Flow Cytometry, Two Tailed Test, One-tailed Test
Journal: Signal Transduction and Targeted Therapy
Article Title: Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
doi: 10.1038/s41392-025-02476-5
Figure Lengend Snippet: T reg cell-mediated intestinal organoid growth requires epithelial IFNγ receptor signaling. a Relative organoid growth of murine SI organoids co-cultured with allogeneic and stimulated (IL-2 + beads) CD4 + CD25 - T conv cells or CD4 + CD25 + T reg cells MACS-isolated from splenocytes of WT C57BL/6 J mice (detailed description of “relative organoid growth” in the methods section and Fig. ). The dotted line represents the growth of control organoids cultured without any T cells. b Relative organoid growth of murine SI organoids co-cultured with allogeneic T conv or T reg cells isolated from Ifng +/+ or Ifng −/− mice. Relative organoid growth of murine SI organoids co-cultured with c allogeneic WT T reg cells in the presence of IFNγ blocking antibody (anti-IFNγ = α-IFNγ) (control organoids were cultured without any T cells but were also stimulated with IL-2 and α-IFNγ) d Murine SI organoids isolated from Ifngr1 +/+ or Ifngr1 −/− mice (C57BL/6 J) were co-cultured with allogeneic WT T reg cells (BALB/c) to analyze relative organoid growth and e mean size (area) after co-culture. Area of murine SI organoids on day 6 after co-culture; number of measured organoids: untreated Ifngr1 +/+ ( n = 167) and Ifngr1 −/− ( n = 163) organoids; Ifngr1 +/+ ( n = 116) and Ifngr1 −/− ( n = 113) organoids with T reg cells. f Exemplary images (converted to grayscale) of organoids after co-culture. g Relative murine SI organoid growth after co-culture with flow cytometry-sorted (CD4 + CD25 hi eGFP-Foxp3 + ) T reg cells ± α-IFNγ (left panel), and h IFNγ expression of T reg cells after removal from co-culture on day 4 and 4 h restimulation (eBioscience™ Cell Stimulation Cocktail plus protein transport inhibitors) (right panel). Violin plots ( e ) showing the distribution of values with medians and quartiles indicated. All other data are presented as the mean ± S.E.M. and were analyzed via an unpaired two-tailed t test or ordinary one-way ANOVA (with Dunn’s multiple comparisons test) for multiple comparisons. The number of biological replicates ( n ), indicating the number of separate organoid culture experiments, is shown in the figure for all individual experiments
Article Snippet: Blocking antibodies (InVivoMAb anti-mouse IL-10R (CD210), InVivoMAb anti-mouse IFNγ,
Techniques: Cell Culture, Isolation, Control, Blocking Assay, Co-Culture Assay, Flow Cytometry, Expressing, Cell Stimulation, Two Tailed Test
Journal: Signal Transduction and Targeted Therapy
Article Title: Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
doi: 10.1038/s41392-025-02476-5
Figure Lengend Snippet: T reg cell-mediated IL-10 and IFNγ co-stimulation promotes murine and human intestinal organoid growth and repair from injury. a Relative growth of murine SI WT organoids co-cultured with allogeneic T reg cells isolated from Ifng +/+ or Ifng −/− mice ± stimulation with 0.25 ng/mL rIFNγ. The dotted line represents the growth of control organoids cultured without any T cells. b Allo-BMT with WT BM plus WT T reg cells and Ifng +/+ or Ifng −/− T conv cells. Intestinal FITC-dextran permeability assay 2 weeks (d16) after allo-BMT. Pooled data from 3 experiments . c Relative organoid growth of murine SI WT organoids co-cultured with allogeneic WT T reg cells ± anti-IL-10R antibody (α-IL10R) or d stimulated with ± 10 ng/mL rIL-10 and ± 0.25 ng/mL rIFNγ in the absence of T reg cells. Relative organoid growth of human patient-derived LI organoids co-cultured with e allogeneic T conv or T reg cells, f with allogeneic T reg cells ± α-IFNγ, or g stimulated ± rIL-10 ± rIFNγ. Left panel: rIFNγ 0.25 ng/mL; right panel: rIFNγ 5 ng/mL. h Relative growth of murine SI organoids after in vitro irradiation ± cytokine stimulation or i ) subsequent co-culture with syngeneic T reg cells. j Ifng +/+ or Ifng −/− mice received ABI (5 × 4.5 Gy/day from day 0 until day 4), and body weight was monitored (treatment schedule is depicted in Fig. ; α-IL10-R injections on day-1, day 3, 7, 10, and 14). Pooled data from 2 experiments. k WT mice received ABI (5×4.5 Gy/day from day 0 until day 4) ± α-IFNγ ± α-IL-10R at the indicated time points (the treatment schedule is depicted in Fig. ; group day 1: injections on days 1, 3, 6, 9, 13, and 16; group day 6: injections on days 6, 9, 13, and 16). Pooled data from 2 experiments. Body weight during regeneration (day 11) was analyzed via ordinary one-way ANOVA plus Fisher’s LSD. The data were analyzed via two-tailed or one-tailed methods ( i , on the basis of the hypothesis of improved T reg -mediated regeneration, as suggested by the results shown in Fig. , ( d , h ). Unpaired t-test or ordinary one-way ANOVA for multiple comparisons (with Dunn’s multiple comparisons test) and are presented as the means ± S.E.M. The number of biological replicates ( n ), indicating the number of separate organoid culture experiments or the number of mice analyzed, is shown in the figure for all individual experiments
Article Snippet: Blocking antibodies (InVivoMAb anti-mouse IL-10R (CD210), InVivoMAb anti-mouse IFNγ,
Techniques: Cell Culture, Isolation, Control, FITC-Dextran Permeability Assay, Derivative Assay, In Vitro, Irradiation, Co-Culture Assay, Two Tailed Test, One-tailed Test
Journal: Signal Transduction and Targeted Therapy
Article Title: Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
doi: 10.1038/s41392-025-02476-5
Figure Lengend Snippet: T reg cells promote organoid growth via mTORC1 and Myc activation in ISCs. Murine SI organoids were co-cultured with CD25 high FoxP3-GFP + T reg cells alone or in the presence of IFNγ and IL-10R blocking antibodies, or were stimulated with rIFNγ + rIL-10 for 4 days, and subsequently analyzed via scRNA-Seq. The data were pooled from 3 independent experiments. a Plots of single cells in UMAP space for all experimental conditions, colored by SingleR cell type annotation. b Venn diagrams indicating the overlap of upregulated pathways between experimental conditions and control organoids. Only gene sets/pathways significantly upregulated when controlling for an FDR of 10% were considered. c Heatmap of Pearson correlation coefficients obtained from correlating GSEA-derived NESs (normalized enrichment scores) between conditions. The values indicate correlations of regulated gene sets/pathway activation between different conditions in the indicated cell types. Only gene sets/pathways significantly up- or downregulated when controlling for an FDR of 10% were considered. d Dot plot of the GSEA results of selected pathways/gene sets for different cell types and treatments (vs. control). Dots are colored according to the negative log 10 of the GSEA q value (FDR), and the sign indicates the direction of the regulation (up positive, down negative). The size of the dots corresponds to the GSEA NES. Gene sets/pathways are derived from the Hallmark (H) and Reactome (R) gene set collections of MSigDB. e Relative organoid growth of SI WT organoids ± stimulation with 0.25 ng/mL rIFNγ and rIL-10 and ± the mTOR inhibitor rapamycin (1 µg/mL) or control (DMSO), f ± myc inhibition (compound 10058-F4, 100 µM/mL) or control (DMSO), and g ± co-cultured T reg cells ± myc inhibition ± mTOR inhibitor. The dotted line represents the growth of control organoids without stimulation. The number of biological replicates ( n ), indicating the number of separate organoid culture experiments, is shown in the figure. The data were analyzed via ordinary one-way ANOVA for multiple comparisons and are presented as the means ± S.E.M.s
Article Snippet: Blocking antibodies (InVivoMAb anti-mouse IL-10R (CD210), InVivoMAb anti-mouse IFNγ,
Techniques: Activation Assay, Cell Culture, Blocking Assay, Control, Derivative Assay, Inhibition
Journal: Signal Transduction and Targeted Therapy
Article Title: Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
doi: 10.1038/s41392-025-02476-5
Figure Lengend Snippet: IFNγ and IL-10 compensate for the depletion of epithelial growth factors. Murine SI organoids were cultured under normal growth conditions (ENR) or EGF-depleted conditions (NR + anti-EGF antibody) and stimulated with the indicated cytokines. a Representative images, b quantification of organoid size on day 6 of culture, c relative organoid growth (number of organoids after first passage, compared with control conditions) ( n = 4 independent experiments), and d relative organoid growth during long-term culture and several passages ( n = 3 independent experiments). e Relative organoid growth of murine SI organoids as described above ± mTOR or myc inhibitors ( n = 4 independent experiments). f Human LI organoids were cultured under optimal (WENR) or EGF-depleted (WNR) conditions and stimulated with the indicated cytokines ± mTOR or myc inhibitors. The area of viable organoids per image (used as a surrogate marker for organoid size) was determined on day 6, and g ) the relative organoid growth (number of viable organoids) was determined after the first passage ( n = 4 independent experiments). h Murine SI organoids were stimulated for 16 h with the indicated cytokines (representative plots). i The cell cycle phase was analyzed to distinguish proliferating (G1/2/S/M phase) and non-proliferating (G0 phase) cells ( n = 6 independent experiments). The proportion of proliferating cells was statistically analyzed. j Murine SI organoids were stimulated for 5 days with the indicated cytokines, and the abundance of Lrg5+ ISCs among all viable epithelial cells (EpCAM + ) and k the number of proliferating (EdU + ) cells among all viable epithelial cells were determined via flow cytometry ( n = 5 independent experiments). l Human LI organoids were subjected to Wnt-depleted conditions (ENR) and stimulated with the indicated cytokines or Wnt. Organoid size on day 6 of culture ( n = 7 independent experiments). m Human LI organoids were cultured under Wnt-depleted conditions and stimulated with the indicated cytokines or Wnt. The number of viable organoids was determined on day 6 of culture ( n = 4 independent experiments). n Murine SI organoids were cultured and mechanically disrupted. One hundred organoids were seeded into culture and stimulated with the indicated cytokines immediately ( < 5 min) or after 90 min. The number of viable organoids was determined on day 6 of culture ( n = 6–15 engraftment culture wells from 3–6 independent experiments). o Analysis of Ifng +/+ and Ifng −/− mice on day 7 after starting ABI (5 × 4.5 Gy/day from day 0 until day 4). The number of Ki-67 + epithelial cells within SI epithelial crypt cells was quantified, and p representative immunohistochemistry images are shown. Data from 2 independent experiments with n = 9 Ifng +/+ mice and n = 9 Ifng −/− mice were pooled, and a total of 131 crypts were analyzed. q The number of Lgr5 + (Lgr5-GFP + ) ISCs within small intestinal epithelial crypts was quantified, and r representative in situ hybridization images are shown. Data from 2 independent experiments with n = 7 Ifng +/+ mice and n = 9 Ifng −/− mice were pooled, and a total of 993 crypts were analyzed. Violin plots ( o , q ) showing the distribution of values, with medians (solid lines) and quartiles (dotted lines) indicated. All the other data are presented as the means ± S.E.M. p values were calculated via two-tailed t tests or ordinary one-way ANOVA for multiple comparisons
Article Snippet: Blocking antibodies (InVivoMAb anti-mouse IL-10R (CD210), InVivoMAb anti-mouse IFNγ,
Techniques: Cell Culture, Control, Marker, Flow Cytometry, Immunohistochemistry, In Situ Hybridization, Two Tailed Test
Journal: Cancer Discovery
Article Title: Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation
doi: 10.1158/2159-8290.CD-24-0415
Figure Lengend Snippet: HPGDS expression in macrophages is sustained byprotumoral cytokines and is downmodulated by activated T cells. A, Violin plot comparing Hpgds expression between Ifn + and Mrc1 + macrophages, extracted from a publicly available scRNA-seq dataset. B, Hpgds expression assessed by qRT-PCR in monocytes (CD45 + , CD11b + , and CD115 + ) and TAMs (CD45 + , CD11b + , and F4/80 + ) from melanoma-bearing mice ( n = 3). C, qRT-PCR analysis of the expression of Hpgds in BMDMs Ctrl or stimulated with antitumoral stimuli (i.e., IFNγ with LPS), protumoral cytokines (i.e., IL-4, IL-6, and IL-10) or with IL-4 and after IL-4 washout, with antitumoral stimuli (e.g., TNFα, IFNγ, and LPS, alone or in combination; n = 3). D, Extracellular levels of PGD 2 measured by ELISA in BMDMs Ctrl or stimulated with IL-4 or first with IL-4 and then with TNFα ( n = 3). E, qRT-PCR analysis showing the regulation of Hpgds expression in IL-4–polarized BMDMs alone (Ctrl) or cocultured with preactivated CD8 + T cells or CD8 + T-cell CM with an isotype or an αTNFα blocking antibody ( n = 3–4). F and G, Tumor growth of resistant (YUMM 1.7; F ) vs. responsive (YUMMER 1.7; G ) melanoma tumors treated with IgG control, αCD8 antibody, αPD1, or the combination of αCD8 and αPD1 ( n = 3–4). H and I, Quantification ( H ) and representative images ( I ) of HPGDS + macrophages in resistant (YUMM 1.7) vs. responsive (YUMMER 1.7) melanoma tumors treated with IgG control, αCD8 antibody, αPD1, or the combination of αCD8 and αPD1 ( n = 3–4). J, Quantification of CD206 + immunosuppressive macrophages in resistant (YUMM 1.7) vs. responsive (YUMMER 1.7) melanoma tumors treated with IgG control, αCD8 antibody, αPD1 or the combination of αCD8 and αPD1 ( n = 3–4). K, Quantification of vessel density in resistant (YUMM 1.7) vs. responsive (YUMMER 1.7) melanoma tumors treated with IgG control, αCD8 antibody, αPD1, or the combination of αCD8 and αPD1 ( n = 3–4). L and M, Quantification ( L ) and representative images ( M ) of αSMA + pericyte blood vessel coverage of YUMM 1.7 or YUMMER 1.7 melanoma-bearing mice treated with IgG, αCD8, αPD1, or the combination of αCD8 and αPD1 ( n = 3–4). N, Tumor growth of YUMMER 1.7 melanoma-bearing mice treated with IgG, αPD1, or αPD1 combined with Enbrel ( n = 8–9). O, Quantification of F4/80 + macrophages in YUMMER 1.7 melanoma tumors treated with IgG, αPD1, or αPD1 in combination with Enbrel. In the group treated with αPD1, three out of nine tumors regressed completely; thus, the staining was not performed ( n = 6–9). P and Q, Quantification ( P ) and representative images ( Q ) of HPGDS + macrophages in YUMMER 1.7 melanoma tumors treated with IgG, αPD1, or αPD1 in combination with Enbrel. In the group treated with αPD1, three out of nine tumors regressed completely; thus, further analyses were not performed ( n = 6–9). P values are calculated by ( A) two-sided Wilcoxon test, ( B ) unpaired, two-tailed Student t test, ( C ) one-way ANOVA with Dunnett correction, and ( D , E , H , J , K , –L , O , and P ) one-way ANOVA with the Tukey multiple comparison test. F , G and N, two-way repeated measures ANOVA. Graphs show the mean ± SEM. I , L and Q, Scale bar: 20 μm.
Article Snippet: When indicated, 25 μg/mL αTNFα, 20 μg/mL
Techniques: Expressing, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Blocking Assay, Control, Staining, Two Tailed Test, Comparison